# Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

> **NCT02133183** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Sapanisertib
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT02133183
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07-02
- **Primary completion:** 2020-01-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Other - Lapse in funding
- **Last updated:** 2024-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02133183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02133183, "Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02133183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*